Qiagen (NYSE:QGEN) Announces Earnings Results

Qiagen (NYSE:QGEN) released its quarterly earnings data on Wednesday. The company reported $0.65 EPS for the quarter, topping the consensus estimate of $0.63 by $0.02, Zacks reports. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The company’s revenue was up 2.8% on a year-over-year basis. During the same period last year, the firm posted $0.61 EPS.

Qiagen Price Performance

QGEN stock traded up $0.44 during trading on Wednesday, hitting $50.82. The stock had a trading volume of 3,228,032 shares, compared to its average volume of 5,863,858. Qiagen has a twelve month low of $32.53 and a twelve month high of $57.81. The company’s 50-day moving average price is $45.55 and its two-hundred day moving average price is $42.77. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31. The stock has a market capitalization of $10.47 billion, a P/E ratio of 26.04, a PEG ratio of 5.01 and a beta of 0.56.

Analyst Ratings Changes

Several research firms recently issued reports on QGEN. Barclays cut shares of Qiagen from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $55.00 to $53.00 in a research note on Wednesday, October 28th. Stifel Nicolaus set a $40.00 price objective on shares of Qiagen in a report on Friday, August 7th. Morgan Stanley reaffirmed an “overweight” rating on shares of Qiagen in a report on Friday, September 11th. UBS Group initiated coverage on shares of Qiagen in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $47.00 price objective for the company. Finally, DZ Bank lowered shares of Qiagen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 22nd. Four equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $46.09.

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.